MedTrace Logo

Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study

NCT02265874 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if nicotine treatment is beneficial for the treatment of sarcoidosis. Sarcoidosis is a disease of unknown cause that leads to inflammation. This disease affects your body's organs.

Conditions

  • Sarcoidosis

Interventions

DRUG

Habitrol

Patch used daily for 28 weeks

DRUG

Placebo to Habitrol

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • Ohio State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-21
Primary Completion
2021-11-01
Completion
2021-11-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02265874 on ClinicalTrials.gov